Introduction: Invasive fungal infections are a primary cause of morbidity and mortality in patients with haematological malignancies. Case Presentation: We describe an unusual clinical and radiological presentation of invasive mucormycosis (IM) in a 69-year-old patient with relapsed acute myeloid leukaemia. The patient was diagnosed with disseminated IM with involvement of the central nervous system in an atypical location, lung, spleen, muscle, bone, and heart, after having completed induction and bridging chemotherapy to allogeneic haematopoietic stem cell transplant (HSCT). Her clinical presentation was atypical with mild neurological symptoms slowly progressing over 2 months and without appropriate signs of systemic inflammation. Mucorales was eventually confirmed from bronchoalveolar lavage and subdural collection. Conclusion: This report highlights the difficult challenges of managing disseminated IM in an immunocompromised patient, where close multidisciplinary specialist care enabled successful treatment, followed by T-cell-depleted allogeneic HSCT for a high-risk haematological malignancy.

1.
Yang
N
,
Zhang
L
,
Feng
S
.
Clinical features and treatment progress of invasive mucormycosis in patients with hematological malignancies
.
J Fungi
.
2023
;
9
(
5
):
592
.
2.
Roden
MM
,
Zaoutis
TE
,
Buchanan
WL
,
Knudsen
TA
,
Sarkisova
TA
,
Schaufele
RL
, et al
.
Epidemiology and outcome of zygomycosis: a review of 929 reported cases
.
Clin Infect Dis
.
2005
;
41
(
5
):
634
53
.
3.
Lanternier
F
,
Sun
HY
,
Ribaud
P
,
Singh
N
,
Kontoyiannis
DP
,
Lortholary
O
.
Mucormycosis in organ and stem cell transplant recipients
.
Clin Infect Dis
.
2012
;
54
(
11
):
1
8
.
4.
Park
BJ
,
Pappas
PG
,
Wannemuehler
KA
,
Alexander
BD
,
Anaissie
EJ
,
Andes
DR
, et al
.
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006
.
Emerg Infect Dis
.
2011
;
17
(
10
):
1855
64
.
5.
Amin
A
,
Chow
MY
.
Pulmonary mucormycosis treated with combination antifungals and lobectomy prior to stem cell transplant in a patient with AML
.
Chest
.
2019
;
156
(
4
):
A629
.
6.
Avivi
I
,
Oren
I
,
Haddad
N
,
Rowe
JM
,
Dann
EJ
.
Stem cell transplantation post invasive fungal infection is a feasible task
.
Am J Hematol
.
2004
;
75
(
1
):
6
11
.
7.
Yazdi
M
,
Behnaminia
N
,
Nafari
A
,
Sepahvand
A
.
Genetic susceptibility to fungal infections
.
Adv Biomed Res
.
2023
;
12
:
248
.
8.
Navarro-Mendoza
MI
,
Pérez-Arques
C
,
Murcia
L
,
Martínez-García
P
,
Lax
C
,
Sanchis
M
, et al
.
Components of a new gene family of ferroxidases involved in virulence are functionally specialized in fungal dimorphism
.
Sci Rep
.
2018
;
8
(
1
):
7660
.
9.
Mishra
A
,
Prabhuraj
AR
,
Shukla
DP
,
Nandeesh
BN
,
Chandrashekar
N
,
Ramalingaiah
A
, et al
.
Intracranial fungal granuloma: a single-institute study of 90 cases over 18 years
.
Neurosurg Focus
.
2019
;
47
(
2
):
E14
.
10.
Mathur
M
,
Johnson
CE
,
Sze
G
.
Fungal infections of the central nervous system
.
Neuroimaging Clin N Am
.
2012
;
22
(
4
):
609
32
.
11.
Schelenz
S
,
Barnes
RA
,
Barton
RC
,
Cleverley
JR
,
Lucas
SB
,
Kibbler
CC
, et al
.
British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases
.
Lancet Infect Dis
.
2015
;
15
(
4
):
461
74
.
12.
Walsh
TJ
,
Gamaletsou
MN
,
McGinnis
MR
,
Hayden
RT
,
Kontoyiannis
DP
.
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)
.
Clin Infect Dis
.
2012
;
54
(
Suppl 1
):
S55
60
.
13.
Cornely
OA
,
Arikan-Akdagli
S
,
Dannaoui
E
,
Groll
AH
,
Lagrou
K
,
Chakrabarti
A
, et al
.
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
.
Clin Microbiol Infect
.
2014
;
20
(
Suppl 3
):
5
26
.
14.
Cornely
OA
,
Alastruey-Izquierdo
A
,
Arenz
D
,
Chen
SCA
,
Dannaoui
E
,
Hochhegger
B
, et al
.
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
.
Lancet Infect Dis
.
2019
;
19
(
12
):
e405
21
.
15.
Tissot
F
,
Agrawal
S
,
Pagano
L
,
Petrikkos
G
,
Groll
AH
,
Skiada
A
, et al
.
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients
.
Haematologica
.
2017
;
102
(
3
):
433
44
.
16.
Pagano
L
,
Cornely
OA
,
Busca
A
,
Caira
M
,
Cesaro
S
,
Gasbarrino
C
, et al
.
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries
.
Haematologica
.
2013
;
98
(
10
):
e127
30
.
17.
Miller
MA
,
Molina
KC
,
Gutman
JA
,
Scherger
S
,
Lum
JM
,
Mossad
SB
, et al
.
Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents
.
Open Forum Infect Dis
.
2021
;
8
(
2
):
ofaa646
.
18.
Penack
O
,
Tridello
G
,
Hoek
J
,
Socié
G
,
Blaise
D
,
Passweg
J
, et al
.
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the infectious diseases and acute leukemia working parties
.
Bone Marrow Transpl
.
2016
;
51
(
3
):
418
23
.
19.
Maziarz
RT
,
Brazauskas
R
,
Chen
M
,
McLeod
AA
,
Martino
R
,
Wingard
JR
, et al
.
Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study
.
Bone Marrow Transpl
.
2017
;
52
(
2
):
270
8
.
You do not currently have access to this content.